Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD123 CAR-T cells (Hebei Senlang Biotechnology)
- Development stage
- Unknown
- Lead developer
- Senlang Bio
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CD123 CAR-T cells (Hebei Senlang Biotechnology) is an autologous chimeric antigen receptor (CAR) T-cell therapy designed to target the CD123 antigen, also known as the alpha subunit of the interleukin-3 receptor (IL-3Rα). CD123 is frequently overexpressed on the surface of leukemic blasts and leukemic stem cells in patients with acute myeloid leukemia (AML), while showing limited expression on normal hematopoietic stem cells, making it a viable therapeutic target. The manufacturing process involves collecting a patient's peripheral blood mononuclear cells, genetically modifying the T cells with a lentiviral vector to express the anti-CD123 CAR, and expanding them in vitro. Upon re-infusion, these engineered T cells recognize and bind to CD123-expressing tumor cells, leading to targeted cell lysis. Hebei Senlang Biotechnology is currently evaluating this therapy in Phase I clinical trials for relapsed or refractory AML.
- Other names
- CD123-targeting CAR-T cellsCD-123-targeting CAR-T cellsCD 123-targeting CAR-T cellsanti-CD123 CAR-T cellsanti-CD-123 CAR-T cellsanti-CD 123 CAR-T cells
02
Targets
IL3RA (Interleukin 3 Receptor)
Beyond the preview
Go deeper on CD123 CAR-T cells (Hebei Senlang Biotechnology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD123 CAR-T cells (Hebei Senlang Biotechnology).